Stuart J. McKinnon, MD, PhD

Related Content

Locations

• Duke Eye Center
• Duke Eye of North Durham

Services

• Duke Eye Center

Department / Division:
Ophthalmology / Glaucoma Service

Address:
DUMC 3802
Durham, NC 27710

Appointment Telephone:
(919) 681-3937

Fax Telephone:
(919) 681-8267

• M.D., LSU Medical Center, Louisiana, 1990

• Ophthalmology, LSU Eye Center, Louisiana, 1995

• Glaucoma, Johns Hopkins School of Medicine, Maryland, 1996

• Ph.D., Physical Chemistry, University of New Orleans, Louisiana, 1990

Clinical Interests:
Diagnosis and treatment of glaucoma and cataract, laser and filtering procedures for glaucoma, complicated cataract surgery

Research Interests:
Stuart J. McKinnon, MD, PhD, specializes in the diagnosis and treatment of glaucoma and cataract. His areas of expertise include open and closed angle glaucomas, neovascular and other secondary glaucomas, and juvenile glaucoma. He is experienced in all forms of anterior segment procedures including laser therapy and filtering surgeries for glaucoma, as well as cataract surgery. He is integrally involved in the teaching of medical students, residents, and fellows. McKinnon's research activities include NIH-sponsored exploration of the basic mechanisms of retinal cell death in glaucoma. Other research areas include neuroprotective glaucoma therapies, non-invasive imaging of glaucoma damage, and relationships between glaucoma and other chronic neurodegenerations such as Alzheimer's disease.

Representative Publications:
Mayo GL, Carter JE, McKinnon SJ. Bilateral optic disk edema and blindness as initial presentation of acute lymphocytic leukemia. Am J Ophthalmol. 2002 Jul;134(1):141-2. (2002) Abstract

Mayo GL, Melendez RF, Kumar N, McKinnon SJ, Glickman RD. Antibody-targeted photodynamic therapy. Am J Ophthalmol. 2003 Dec;136(6):1151-2. (2003) Abstract

Reitsamer HA, Kiel JW, Harrison JM, Ransom NL, McKinnon SJ. Tonopen measurement of intraocular pressure in mice. Exp Eye Res. 2004 Apr;78(4):799-804. (2004) Abstract

McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, Ransom NL, Tahzib NG, Reitsamer HA, Levkovitch-Verbin H, Quigley HA, Zack DJ. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1077-87. (2002) Abstract

McKinnon SJ. Glaucoma: ocular Alzheimer's disease? Front Biosci. 2003 Sep 1;8:s1140-56. (2003) Abstract

Jacob JT, Burgoyne CF, McKinnon SJ, Tanji TM, LaFleur PK, Duzman E. Biocompatibility response to modified Baerveldt glaucoma drains. J Biomed Mater Res. 1998;43(2):99-107. (1998) Abstract

Ivanov D, Dvoriantchikova G, Nathanson L, McKinnon SJ, Shestopalov VI. Microarray analysis of gene expression in adult retinal ganglion cells. FEBS Lett. 2006 Jan 9;580(1):331-5. (2006) Abstract

Tahzib NG, Ransom NL, Reitsamer HA, McKinnon SJ. Alpha-fodrin is cleaved by caspase-3 in a chronic ocular hypertensive (COH) rat model of glaucoma. Brain Res Bull. 2004 Feb 15;62(6):491-5. (2004) Abstract

McKinnon SJ, Lehman DM, Tahzib NG, Ransom NL, Reitsamer HA, Liston P, LaCasse E, Li Q, Korneluk RG, Hauswirth WW. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002 Jun;5(6):780-7. (2002) Abstract

McKinnon SJ. Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol. 1997 Apr;8(2):28-37. (1997) Abstract

Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000 Mar;41(3):764-74. (2000) Abstract

Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, Mitchell RS. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3460-6. (2000) Abstract

Sponsel WE, Paris G, Trigo Y, Pena M, Weber A, Sanford K, McKinnon S. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol. 2002 Jan;133(1):11-8. (2002) Abstract

Whittenburg SL, Jain VK, McKinnon SJ. Depolarized Rayleigh Scattering Study of Neat Formamide. J Phys Chem 1986 90:1004-1005. (1986)

Homer SR, McKinnon SJ, Whittenburg SL. A Series of  Experiments with 2-methyl-2-nitrosopropane: A Physical Chemistry Laboratory Experiment. J Chem Ed  1987 63:1103-1104. (1987)

Goodman MA, Jain VK, McKinnon SJ, Whittenburg SL. Hypersonic Attenuation of the Simple Amides. J Phys Chem  1987 91:1634-1638. (1987)

Whittenburg SL, McKinnon SJ, Jain VK, Evilia RF, Depolarized Rayleigh Light Scattering Study and NMR Spectroscopy of m-cresol and p-cresol. J Phys Chem 1988 92:4236-4241. (1988)

Goodman MA, McKinnon SJ, Jain VK, Whittenburg SL. Hypersonic Attenuation in Simple Cresols. J Phys Chem 1989 93:6832-6835. (1989)

Whittenburg SL, Jain VK, McKinnon SJ. Depolarized Rayleigh Scattering Study of Pyrimidine. J Mol Liq 1990 47:161-169. (1990)

McKinnon SJ, Whittenburg SL, Brooks BR. Nonequilibrium Molecular Dynamics Simulation of Oxygen Diffusion Through Hexadecane Monolayers with Varying Concentrations of Cholesterol. J Phys Chem 1992 96:10497-10506. (1992)

Lowenstein A, McKinnon SJ, DiBernardo C. Echographic Diagnosis of Scleral Fold in Hypotony. Am J Ophthalmol 1997 4:260. (1997)

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30. (2002) Abstract

Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA, . The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004 Jun;122(6):813-20. (2004) Abstract

Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. (2002) Abstract

Feuer WJ, Parrish RK 2nd, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO. The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol. 2002 Jan;133(1):19-28. (2002) Abstract

Keltner JL, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO. Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005 Sep;123(9):1201-6. (2005) Abstract

Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, . Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology. 2002 Mar;109(3):432-7. (2002) Abstract

Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol. 2000 Sep;118(9):1187-94. (2000) Abstract

Brandt JD, Beiser JA, Gordon MO, Kass MA, . Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004 Nov;138(5):717-22. (2004) Abstract

Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001 Oct;108(10):1779-88. (2001) Abstract

Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO, . Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol. 2003 May;121(5):643-50. (2003) Abstract

Coleman AL, Gordon MO, Beiser JA, Kass MA, . Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004 Oct;138(4):684-5. (2004) Abstract

Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999 May;117(5):573-83. (1999) Abstract